Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2021 - 2025)

Ani Pharmaceuticals' Preferred Stock Liabilities history spans 6 years, with the latest figure at $24.8 million for Q2 2025.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $24.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $24.8 million, a 0.0% change, with the full-year FY2024 number at $24.8 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities hit $24.8 million in Q2 2025 for Ani Pharmaceuticals, roughly flat from $24.8 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for ANIP hit a ceiling of $24.8 million in Q4 2021 and a floor of $24.8 million in Q4 2021.
  • Historically, Preferred Stock Liabilities has averaged $24.8 million across 5 years, with a median of $24.8 million in 2021.
  • The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2022, down 0.0% in 2022.
  • Tracing ANIP's Preferred Stock Liabilities over 5 years: stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
  • Business Quant data shows Preferred Stock Liabilities for ANIP at $24.8 million in Q2 2025, $24.8 million in Q1 2025, and $24.8 million in Q4 2024.